Current and future management approaches for rheumatoid arthritis
Open Access
- 1 January 2002
- journal article
- review article
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 4 (Suppl 2) , S16-S21
Abstract
With the introduction of new disease-modifying antirheumatic drugs (DMARDs) and other therapeutic agents, the management of rheumatoid arthritis (RA) has shifted toward earlier, more aggressive therapy. The ultimate goal is to prevent structural joint damage that leads to pain and functional disability. Early diagnosis of RA is therefore essential, and early DMARD treatment combined with nonsteroidal anti-inflammatory drugs is recommended. Combination DMARD regimens and new biologic agents (anti-tumor necrosis factor [TNF] therapies [infliximab, etanercept] and the interleukin [IL]-1 antagonist [anakinra]) have emerged as viable options for early treatment of RA patients. These new biologic agents and future nonbiologic agents that target proteins in signaling cascades are likely to change the landscape of RA treatments.Keywords
This publication has 45 references indexed in Scilit:
- American College of Rheumatology criteria for improvement in rheumatoid arthritis should only be calculated from scores that decrease on improvementArthritis & Rheumatism, 2001
- Rational Use of New and Existing Disease-Modifying Agents in Rheumatoid ArthritisAnnals of Internal Medicine, 2001
- Treatment of rheumatoid arthritis patients with interleukin-1 receptor antagonist: Radiologic assessmentSeminars in Arthritis and Rheumatism, 2001
- Infliximab and Methotrexate in the Treatment of Rheumatoid ArthritisNew England Journal of Medicine, 2000
- A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Leflunomide Suppresses TNF-Induced Cellular Responses: Effects on NF-κB, Activator Protein-1, c-Jun N-Terminal Protein Kinase, and ApoptosisThe Journal of Immunology, 2000
- Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000)Annals of the Rheumatic Diseases, 2000
- Leflunomide: mode of action in the treatment of rheumatoid arthritisAnnals of the Rheumatic Diseases, 2000
- A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritisRheumatology, 2000
- Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritisArthritis & Rheumatism, 1999